1. [Successful use of vemurafenib in a patient with resistant hairy cell leukemia].
- Author
-
Urnova ES, Al'-Radi LS, Kuz'mina LA, Kariakina AA, Kovrigina AM, Dvirnyk VN, Iakutik IA, Sudarikov AB, Parovichnikova EN, and Savchenko VG
- Subjects
- Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Humans, Indoles administration & dosage, Indoles adverse effects, Leukemia, Hairy Cell complications, Leukemia, Hairy Cell surgery, Male, Middle Aged, Splenectomy, Splenomegaly complications, Splenomegaly surgery, Sulfonamides administration & dosage, Sulfonamides adverse effects, Treatment Outcome, Vemurafenib, Antineoplastic Agents therapeutic use, Drug Resistance, Neoplasm, Indoles therapeutic use, Leukemia, Hairy Cell drug therapy, Sulfonamides therapeutic use
- Abstract
The paper describes a case of a patient with refractory hairy cell leukemia. In spite of the absence of CD25 expression, the disease was classified as a classical form according to the WHO classification (2008), as also confirmed by the detection of BRAFV600E mutation. The disease was characterized by resistance to all lines of therapy (interferon-a, splenectomy, cladribin). Clinical and hematological remission was achieved within 2 months of administration of the BRAF kinase inhibitor vemurafenib.
- Published
- 2013